Caris Life Sciences (CAI) announced a study published in Scientific Reports, a Nature journal, demonstrating the utility of the Caris Assure blood-based biopsy assay across the cancer continuum. The Caris Assure liquid biopsy platform, powered by the Assure Blood-based Cancer Detection AI, was trained on over 376,000 whole exome and whole transcriptome tissue profiles and over 7,000 matched blood and tissue samples. Caris Assure : achieved sensitivities of 83.1% to 95.7% across cancer stages I-IV at 99.6% specificity; accurately identified the diagnostic pathway for MCED-positive cancers using the ABCDai-GPS model and demonstrated significant predictive power for recurrence, with hazard ratios of 33.4 for MRD and 4.39 for therapeutic monitoring.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences vice chairman Brille buys 30,000 common shares
- Opening Day: Caris jumps as investors buy into ‘AI TechBio company’
- Two new option listings and nine option delistings on June 23rd
- Caris Life Sciences 23.53M share IPO priced at $21.00
- Caris Life Sciences indicated to open at $30, IPO priced at $21 per share